Table 1.
Ghrelin receptor agonists (GH secretagogues) for human health
| Compound | Synonyms | Company | Peptide/Chemical | Phase | Indication |
|---|---|---|---|---|---|
| Anamorelin |
ONO‐7643 ST‐1291 RC‐1291 |
Helsinn Ono (JP) (Sapphire, Rejuvenon) |
Chemical | Phase 3 | Cancer cachexia |
| Capromorelin |
CP‐424,391 RQ‐00000005 |
Pfizer Raqualia | Chemical | Phase 2, discontinued | Frailty in elderly |
| Examorelin |
Hexarelin EP‐23905 MF‐6003 |
(Europeptides, Mediolanum Farmaceutici) |
Peptide | Phase 2, discontinued | GH deficiency |
| Ibutamoren | MK‐0677 | Merck | Chemical | Phase 2, discontinued |
Fibromyalgia Alzheimer's disease Frailty in elderly |
| Ipamorelin | NNC 26‐0161 |
Helsinn (Novo Nordisk) |
Peptide | Phase 2, discontinued | Postoperative ileus |
| Macimorelin |
AEZS‐130 EP1572 JMV‐1843 |
Aeterna Zentaris | Chemical | Phase 3 | Evaluation of adult GH deficiency |
| Pralmorelin |
GHRP 2 GPA 748 KP‐102 |
Kaken | Peptide | Approved in Japan | Evaluation of GH deficiency |
| Relamorelin |
BIM‐28131 RM 131 |
Allergan (Motus, Rhythm, Ipsen) |
Peptide | Phase 2 | Diabetic gastroparesis |
| Sermorelin | GRF 1‐29 | Serono | Peptide | Approved US, discontinued | GH deficiency |
| Tabimorelin |
NN‐703 NNC 26‐0703 |
Novo Nordisk | Chemical | Phase 2, discontinued | GH deficiency |
| Ulimorelin |
LP101 TZP‐101 |
Lyric (US) (Tranzyme) Norgine (ex US) |
Peptide | Phase 2 | Nutrition disorders |